Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Withdrawn) A process for the preparation of isotonic oil emulsions for intravenous administration, comprising the steps of:

providing at least one of estrogens and progestagens;

providing an oil phase and an aqueous phase;

providing an antioxidant;

dissolving the at least one of estrogen and progestagen in the oil phase; and

emulsifying the oil phase in the aqueous phase; in the presence of an emulsifier.

2. (Currently Amended) A hormone-containing isotonic oil emulsion for intravenous administration comprising:

at least one [[of]] progestagens[[s]] and at least one estrogen[[s]];

an oil phase;

an antioxidant;

an emulsifier; and

an aqueous phase;

wherein the at least one ~~of the~~ progestagens[[s]] and the at least one estrogen[[s]] are dissolved in the oil phase prior to being mixed with the aqueous phase.

3. (Currently Amended) The hormone-containing isotonic oil emulsion for intravenous administration according to claim 2, comprising the at least one progestagens[[s]] and the at least one estrogen[[s]] in a ratio of from 2:1 to 200:1.

4. (Currently Amended) The oil emulsion according to claim 2, characterized in that the emulsion contains from 0.005 to 0.5% by weight of the at least[[an]] one estrogen and from 0.05 to 5% by weight of [[a]]the at least one progestagen, based on the total composition.

5. (Currently Amended) The oil emulsion according to claim 2, characterized in that ~~said~~ the at least one estrogen is estradiol and ~~said~~ the at least one progestagen is progesterone.

6. (Currently Amended) The oil emulsion according to claim 2, characterized in that said oil phase comprises medium chain triglycerides (MCT) having a chain length of from 6 to 12~~, preferably from 8 to 10,~~ carbon atoms.

7. (Currently Amended) The oil emulsion according to claim 2, characterized by containing [[up]]from 0.6% to 1.5% by weight of the emulsifier, based on the total composition.

8. (Withdrawn) Use of the isotonic oil emulsion according to any of claims 2 to 7 for preparing a medicament for intravenous administration of estrogen and progestagen for postnatal hormone substitution in premature babies.

9. (Withdrawn) Use of the isotonic oil emulsion according to any of claims 2 to 7 for preparing a medicament for the treatment of neurological damage after strokes.

10. (Withdrawn) A process for hormone substitution in premature babies by using the isotonic oil emulsion according to any of claims 2 to 7.

11. (Withdrawn) A process for the treatment of neurological damage after strokes by using the isotonic oil emulsion according to any of claims 2 to 7.

12. (Previously Presented) The hormone-containing isotonic oil emulsion

for intravenous administration according to claim 2; further comprising a co-emulsifier.

13. (Previously Presented) The hormone-containing isotonic oil emulsion for intravenous administration according to claim 12, wherein the co-emulsifier is present in an amount of from 0.005 to 0.1% by weight, based on the total composition.

14. (Previously Presented) The hormone-containing isotonic oil emulsion for intravenous administration according to claim 2; wherein the antioxidant comprises tocopherols or tocopherol esters.

15. (Previously Presented) The hormone-containing isotonic oil emulsion for intravenous administration according to claim 2; wherein the antioxidant is present in an amount from about 10mg to 1000mg, based on 100g of the oil phase.

16. (Previously Presented) The hormone-containing isotonic oil emulsion for intravenous administration according to claim 2; having a pH value from 6.0 to 9.0.